<rdf:RDF xmlns:api="http://www.elsevier.com/xml/svapi/rdf/dtd/" xmlns:dc="http://purl.org/dc/elements/1.1/" xmlns:prism="http://prismstandard.org/namespaces/basic/2.0/" xmlns:rdf="http://www.w3.org/1999/02/22-rdf-syntax-ns#" xmlns:skos="http://www.w3.org/2004/02/skos/core#" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance"><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/79952196706"><dc:identifier>https://api.elsevier.com/content/abstract/eid/2-s2.0-79952196706</dc:identifier><api:scopusId>79952196706</api:scopusId><api:eid>2-s2.0-79952196706</api:eid><api:pubmedId>20466686</api:pubmedId><api:pui>365106162</api:pui><prism:doi>10.1093/ndt/gfq256</prism:doi><dc:title>Long-term efficacy and safety of rituximab in refractory and relapsing systemic lupus erythematosus</dc:title><prism:issn>09310509</prism:issn><prism:issn>14602385</prism:issn><prism:contentType>Abstract</prism:contentType><prism:aggregationType>Journal</prism:aggregationType><api:srctype>j</api:srctype><api:subtype>ar</api:subtype><api:subtypeDescription>Article</api:subtypeDescription><api:citedbyCount>55</api:citedbyCount><prism:publicationName>Nephrology Dialysis Transplantation</prism:publicationName><api:sourceId>20021</api:sourceId><prism:volume>25</prism:volume><prism:issueIdentifier>11</prism:issueIdentifier><prism:startingPage>3586</prism:startingPage><prism:endingPage>3592</prism:endingPage><prism:pageRange>3586-3592</prism:pageRange><prism:coverDate>2010-11-01</prism:coverDate><prism:copyrightYear>2010</prism:copyrightYear><dc:creator><rdf:Seq><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/22633811800"><api:authid>22633811800</api:authid><api:surname>Catapano</api:surname><api:givenName>Fausta</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60031101"/><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60001138"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/12766011000"><api:authid>12766011000</api:authid><api:surname>Chaudhry</api:surname><api:givenName>Afzal N.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60031101"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/45761212800"><api:authid>45761212800</api:authid><api:surname>Jones</api:surname><api:givenName>Rachel B.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60031101"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/7410186181"><api:authid>7410186181</api:authid><api:surname>Smith</api:surname><api:givenName>Kenneth G.C.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60031101"/></api:Author></rdf:li><rdf:li><api:Author rdf:about="https://api.elsevier.com/content/author/author_id/57190283292"><api:authid>57190283292</api:authid><api:surname>Jayne</api:surname><api:givenName>David W.</api:givenName><api:affiliation rdf:resource="https://api.elsevier.com/content/affiliation/affiliation_id/60031101"/></api:Author></rdf:li></rdf:Seq></dc:creator><dc:subject rdf:resource="http://data.elsevier.com/vocabulary/ASJC/2727"/><dc:subject rdf:resource="http://data.elsevier.com/vocabulary/ASJC/2747"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/21344443488"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0002914609"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0029046927"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0027380153"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/0034861959"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/3042592452"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/27544508559"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/44349131653"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/56749153905"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/34548151122"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/39549108298"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/34250631349"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33645068869"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/70350525210"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/28544449032"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/13444252282"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/21144438589"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/4043179907"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/33749331884"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/8444223507"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/1442355581"/><api:reference rdf:resource="https://api.elsevier.com/content/abstract/scopus_id/20444466207"/><prism:keyword>B-cell depleting therapy</prism:keyword><prism:keyword>Lupus nephritis</prism:keyword><prism:keyword>Monoclonal antibody</prism:keyword><prism:keyword>Rituximab</prism:keyword><prism:keyword>Systemic lupus erythematosus</prism:keyword><api:scopusPage rdf:resource="https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&amp;scp=79952196706&amp;origin=inward"/></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60031101"><api:afid>60031101</api:afid><skos:prefLabel>University of Cambridge</skos:prefLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/affiliation/affiliation_id/60001138"><api:afid>60001138</api:afid><skos:prefLabel>Azienda Sanitaria Universitaria Integrata di Trieste</skos:prefLabel></rdf:Description><rdf:Description rdf:about="http://data.elsevier.com/vocabulary/ASJC/2727"><api:code>2727</api:code><api:abbrev>MEDI</api:abbrev><skos:prefLabel>Nephrology</skos:prefLabel><skos:altLabel>Medicine</skos:altLabel></rdf:Description><rdf:Description rdf:about="http://data.elsevier.com/vocabulary/ASJC/2747"><api:code>2747</api:code><api:abbrev>MEDI</api:abbrev><skos:prefLabel>Transplantation</skos:prefLabel><skos:altLabel>Medicine</skos:altLabel></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/21344443488"><api:scopusId>21344443488</api:scopusId><dc:title>T- and B-cell abnormalities in systemic lupus erythematosus</dc:title><prism:publicationName>Critical Reviews in Immunology</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>25</prism:volume><prism:startingPage>123</prism:startingPage><prism:endingPage>140</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0002914609"><api:scopusId>0002914609</api:scopusId><prism:publicationName>Systemic Lupus Erythematosus and the Kidney</prism:publicationName><prism:publicationYear>1999</prism:publicationYear><prism:startingPage>657</prism:startingPage><prism:endingPage>685</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0029046927"><api:scopusId>0029046927</api:scopusId><dc:title>Mortality in systemic lupus erythematosus: Results from a single center</dc:title><prism:publicationName>J Rheumatol</prism:publicationName><prism:publicationYear>1995</prism:publicationYear><prism:volume>22</prism:volume><prism:startingPage>1259</prism:startingPage><prism:endingPage>1264</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0027380153"><api:scopusId>0027380153</api:scopusId><dc:title>Risk for sustained amenorrhea in patients with systemic lupus erythematosus receiving intermittent pulse cyclophosphamide therapy</dc:title><prism:publicationName>Annals of Internal Medicine</prism:publicationName><prism:publicationYear>1993</prism:publicationYear><prism:volume>119</prism:volume><prism:startingPage>366</prism:startingPage><prism:endingPage>369</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/0034861959"><api:scopusId>0034861959</api:scopusId><dc:title>Complement activation in circulation and central nervous system after rituximab (anti-CD20) treatment of B-cell lymphoma</dc:title><prism:publicationName>Leukemia and Lymphoma</prism:publicationName><prism:publicationYear>2001</prism:publicationYear><prism:volume>42</prism:volume><prism:startingPage>731</prism:startingPage><prism:endingPage>738</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/3042592452"><api:scopusId>3042592452</api:scopusId><dc:title>The innate mononuclear phagocyte network depletes B lymphocytes through Fc receptor-dependent mechanisms during anti-CD20 antibody immunotherapy</dc:title><prism:publicationName>Journal of Experimental Medicine</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>199</prism:volume><prism:startingPage>1659</prism:startingPage><prism:endingPage>1669</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/27544508559"><api:scopusId>27544508559</api:scopusId><dc:title>Tolerability and safety of rituximab</dc:title><prism:publicationName>Cancer Treat Rev</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>31</prism:volume><prism:startingPage>456</prism:startingPage><prism:endingPage>473</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/44349131653"><api:scopusId>44349131653</api:scopusId><dc:title>Longterm clinical and immunological effects of anti-CD20 treatment in patients with refractory systemic lupus erythematosus</dc:title><prism:publicationName>Journal of Rheumatology</prism:publicationName><prism:publicationYear>2008</prism:publicationYear><prism:volume>35</prism:volume><prism:startingPage>826</prism:startingPage><prism:endingPage>833</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/56749153905"><api:scopusId>56749153905</api:scopusId><dc:title>Variability in the biological response to anti-CD20 B-cell depletion in SLE</dc:title><prism:publicationName>Ann Rheum Dis</prism:publicationName><prism:publicationYear>2008</prism:publicationYear><prism:volume>67</prism:volume><prism:startingPage>1724</prism:startingPage><prism:endingPage>1731</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/34548151122"><api:scopusId>34548151122</api:scopusId><dc:title>B cell depletion therapy in systemic lupus erythematosus: Long-term follow-up and predictors of response</dc:title><prism:publicationName>Annals of the Rheumatic Diseases</prism:publicationName><prism:publicationYear>2007</prism:publicationYear><prism:volume>66</prism:volume><prism:startingPage>1259</prism:startingPage><prism:endingPage>1262</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/39549108298"><api:scopusId>39549108298</api:scopusId><dc:title>Treatment of refractory SLE with rituximab plus cyclophosphamide: Clinical effects, serological changes, and predictors of response</dc:title><prism:publicationName>Annals of the Rheumatic Diseases</prism:publicationName><prism:publicationYear>2008</prism:publicationYear><prism:volume>67</prism:volume><prism:startingPage>330</prism:startingPage><prism:endingPage>334</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/34250631349"><api:scopusId>34250631349</api:scopusId><dc:title>A multicenter phase I/II trial of rituximab for refractory systemic lupus erythematosus</dc:title><prism:publicationName>Modern Rheumatology</prism:publicationName><prism:publicationYear>2007</prism:publicationYear><prism:volume>17</prism:volume><prism:startingPage>191</prism:startingPage><prism:endingPage>197</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33645068869"><api:scopusId>33645068869</api:scopusId><dc:title>Rituximab in refractory autoimmune diseases: Brazilian experience with 29 patients (2002-2004)</dc:title><prism:publicationName>Clin Exp Rheumatol</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>24</prism:volume><prism:startingPage>65</prism:startingPage><prism:endingPage>69</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/70350525210"><api:scopusId>70350525210</api:scopusId><dc:title>Clinical and immunological effects of rituximab in patients with lupus nephritis refractory to conventional therapy: A pilot study</dc:title><prism:publicationName>Arthritis Res Ther</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>8</prism:volume></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/28544449032"><api:scopusId>28544449032</api:scopusId><dc:title>B-cell depletion in the treatment of patients with systemic lupus erythematosus: A longitudinal analysis of 24 patients</dc:title><prism:publicationName>Rheumatology</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>44</prism:volume><prism:startingPage>1542</prism:startingPage><prism:endingPage>1545</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/13444252282"><api:scopusId>13444252282</api:scopusId><dc:title>Remission of proliferative lupus nephritis following B cell depletion therapy is preceded by down-regulation of the T cell costimulatory molecule CD40 ligand: An open-label trial</dc:title><prism:publicationName>Arthritis and Rheumatism</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>52</prism:volume><prism:startingPage>501</prism:startingPage><prism:endingPage>513</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/21144438589"><api:scopusId>21144438589</api:scopusId><dc:title>Tolerance and short term efficacy of rituximab in 43 patients with systemic autoimmune diseases</dc:title><prism:publicationName>Annals of the Rheumatic Diseases</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>64</prism:volume><prism:startingPage>913</prism:startingPage><prism:endingPage>920</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/4043179907"><api:scopusId>4043179907</api:scopusId><dc:title>B cell depletion as a novel treatment for systemic lupus erythematosus: A phase I/II dose-escalation trial of rituximab</dc:title><prism:publicationName>Arthritis and Rheumatism</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>50</prism:volume><prism:startingPage>2580</prism:startingPage><prism:endingPage>2589</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/33749331884"><api:scopusId>33749331884</api:scopusId><dc:title>Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment</dc:title><prism:publicationName>Arthritis and Rheumatism</prism:publicationName><prism:publicationYear>2006</prism:publicationYear><prism:volume>54</prism:volume><prism:startingPage>2970</prism:startingPage><prism:endingPage>2982</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/8444223507"><api:scopusId>8444223507</api:scopusId><dc:title>Rituximab improves peripheral B cell abnormalities in human systemic lupus erythematosus</dc:title><prism:publicationName>Arthritis and Rheumatism</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>50</prism:volume><prism:startingPage>3580</prism:startingPage><prism:endingPage>3590</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/1442355581"><api:scopusId>1442355581</api:scopusId><dc:title>Sequential therapies for proliferative lupus nephritis</dc:title><prism:publicationName>New England Journal of Medicine</prism:publicationName><prism:publicationYear>2004</prism:publicationYear><prism:volume>350</prism:volume><prism:startingPage>971</prism:startingPage><prism:endingPage>980</prism:endingPage></rdf:Description><rdf:Description rdf:about="https://api.elsevier.com/content/abstract/scopus_id/20444466207"><api:scopusId>20444466207</api:scopusId><dc:title>Long-term study of mycophenolate mofetil as continuous induction and maintenance treatment for diffuse proliferative lupus nephritis</dc:title><prism:publicationName>Journal of the American Society of Nephrology</prism:publicationName><prism:publicationYear>2005</prism:publicationYear><prism:volume>16</prism:volume><prism:startingPage>1076</prism:startingPage><prism:endingPage>1084</prism:endingPage></rdf:Description></rdf:RDF>